Adult patients suffering from MI (few days until <35 days), ischaemic stroke (7 days until <6 mth) or established peripheral arterial disease; non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI) ie, patients undergoing stent placement following percutaneous coronary intervention; ST segment elevation acute MI, in combination w/ acetylsalicylic acid (ASA) in medically treated patients eligible for thrombolytic therapy. In combination w/ ASA for the prevention of atherothrombotic & thromboembolic events ie, stroke.
Patients at increased risk of bleeding from trauma, surgery or other pathological conditions & receiving concomitant ASA, heparin, glycoprotein IIb/IIIa inhibitors or NSAIDs including COX-2 inhibitors. Avoid concomitant use w/ oral anticoagulants. Discontinue 7 days prior to surgery. Lesions w/ propensity to bleed (particularly GI & intraocular). Thrombotic thrombocytopenic purpura (TTP). Not recommended during 1st 7 days after acute ischaemic stroke. Avoid concomitant use w/ CYP2C19 inhibitors omeprazole & esomeprazole. Patients undergoing percutaneous coronary intervention. Avoid lapses in therapy. Nasogastric administration in critically ill patients after cardiopulmonary resuscitation. Renal impairment. Moderate hepatic impairment w/ bleeding diatheses. Pregnancy & lactation. Not to be used in childn.
Manage Account
Change Password
Sign Out
